New combo could cut hormone therapy time for prostate cancer patients
NCT ID NCT07550517
First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study tests whether adding a radioactive drug called 177Lu-PSMA-617 to standard radiation therapy can allow men with high-risk localized prostate cancer to take hormone therapy for only 6 months instead of the usual 24 months. The goal is to see if this approach is as effective at controlling cancer while reducing side effects from long-term hormone treatment. The trial will enroll 60 men and compare the two treatment plans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 177Lu-PSMA-617 (a radioactive drug that targets prostate cancer cells)
- What this could lead to
- If successful, this could allow men with high-risk prostate cancer to receive a shorter course of hormone therapy (6 months instead of 24 months), reducing side effects like hot flashes and bone loss while maintaining cancer control.
- What could go wrong
- This is a small, early-phase (phase 2) trial with only 60 participants. The experimental drug may not work as well as the standard long-term hormone therapy, and there is a risk of side effects from the radioactive drug, such as dry mouth or kidney issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK LOCALIZED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.